A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF
NCT ID: NCT01566578
Last Updated: 2012-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
24 participants
INTERVENTIONAL
2012-04-30
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EGF Cream
Human recombinant epidermal growth factor
topical
Placebo cream
Placebo cream
Dermal cream without EGF
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Human recombinant epidermal growth factor
topical
Placebo cream
Dermal cream without EGF
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mild to moderate psoriasis (all types) with active plaques on both body sides accessible for biopsy and self product application
* EGFR immunohistochemistry score \> 5
* Male
* Age 18-60 years
Exclusion Criteria
* Local psoriasis treatment on the investigational sites in the last 30 days or during the study
* Known hypersensitivity or allergy to the EGF containing product (Newskin) and/or to Vaseline/10% salicylic acid and/or to local anaesthetics of the amid type
* Known or suspected non-compliance to study protocol Coagulopathy or treatment with anticoagulants
* History of malignant disease Other clinically relevant concomitant disease state Participation in another investigational drug study in the last 30 days
18 Years
60 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zurich
OTHER
Ennar Pharmaceuticals AF
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Kündig, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Zurich, Dermatology Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Zurich, Dermatology Clinic
Zurich, Canton of Zurich, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Michael Weisskopf, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EGFR-Study
Identifier Type: -
Identifier Source: org_study_id